Skip to main content
Device Global Header

Subscribe
or Renew

Advanced Search

This article is available to subscribers. Subscribe now. Already have an account? Sign in

Review ArticleFree Preview

Gliflozins in the Management of Cardiovascular Disease

List of authors.
  • Eugene Braunwald, M.D.

Gliflozins — sodium–glucose cotransporter 2 inhibitors — lower blood glucose and glycated hemoglobin in patients with type 2 diabetes without causing hypoglycemia. The agents also improve cardiac function in patients who have heart failure with or without type 2 diabetes and improve renal function, with few adverse effects.

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Disclosure forms provided by the author are available with the full text of this article at NEJM.org.

I thank Dr. Thomas A. Zelniker, Medical University of Vienna, for a careful reading of a previous version of the manuscript and useful suggestions, and Ms. Kathryn Saxon for a detailed review of the manuscript.

Author Affiliations

From the TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, and the Department of Medicine, Harvard Medical School, Boston.

Dr. Braunwald can be contacted at or at the TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Hale Building for Transformative Medicine, Suite 7022, 60 Fenwood Rd., Boston, MA 02115.

Print Subscriber? Activate your online access.